Vertex Confirms Supply Chain Continuity and Business Outlook for Its Cystic Fibrosis Medicines and Provides Initial Update on Development Programs

About this update from Vertex Pharmaceuticals Incorporated

[{"type":"text","content":" BOSTON--(BUSINESS WIRE)--\nVertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today confirmed its 2020 business outlook and the continuity of the company’s supply chain for its approved cystic fibrosis (CF) medicines and provided an update on its development programs given the ongoing COVID-19 pandemic.\n\n\n“Despite the widespread impact of the COVID-19 pandemic, the outlook for our business remains unchanged and we continue to be highly confident in our supply chain and our ability to supply all of our approved medicines to patients who need them,” said Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive Officer of Vertex. “The COVID-19 pandemic is a rapidly evolving global health crisis that will require unprecedented utilization of health care resources that we expect will have an impact on our clinical trials. In order to ensure patient safety and the appropriate use of healthcare resources and to maintain study integrity, we have made proactive changes to some of our ongoing and planned clinical trials. Given the rapidly evolving pandemic, it is too early to precisely determine the long-term effects of the outbreak on trial timelines.”\n\n\nBusiness Outlook and Supply Chain:\n\n\nThe global COVID-19 outbreak has not had any impact on the continuity of Vertex’s supply chain for its approved medicines nor on its business outlook for 2020. The company has ample supply to meet commercial needs well into the future and remains highly confident in its ability to continue to supply all of its medicines to patients around the world. Additionally, the company’s manufacturing facilities have remained operational and continue to produce new supply of the company’s medicines.\n\n\nDevelopment Programs:\n\n\nVertex is currently conducting multiple clinical trials globally that span various diseases, modalities and stages of development. These trials include late-stage, post-marketing or confirmatory studies for medicines with well-established benefit-risk profiles, as well as earlier-stage proof-of-concept studies for investigational medicines. For ongoing studies, Vertex is working with clinical trial sites to enable virtual clinic visits and home delivery of study drug to ensure study continuity and medical monitoring, and to facilitate study procedures. Depending on the disease, stage of development and type of stud...

More updates from Vertex Pharmaceuticals Incorporated